Skip to main content
Fig.5 | Journal of Neuroinflammation

Fig.5

From: Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease

Fig.5

Fexofenadine mitigates micro/astro-gliosis in PFF-injected mice. a IHC of GFAP in ipsilateral M1, Cpu and SN regions of PFF or PFF + Fexo. Scale bar indicates 50 μm. Values are derived from the analysis of data collected from PBS (n = 3), PFF (n = 7), or PFF + Fexo (n = 7) groups at 4 weeks post-injection. b IHC of IBA-1 in ipsilateral M1, Cpu and SN regions of PFF or PFF + Fexo groups. Values are derived from the analysis of data collected from PBS (n = 3), PFF (n = 7) or PFF + Fexo (n = 7) groups at 4 weeks post-injection. Scale bar indicates 50 μm. ***p < 0.001, **p < 0.01, *p < 0.05, one-way ANOVA with Tukey’s multiple comparison test

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094